Abstract: Certain new phenone derivatives of the formula (I) ##STR1## in which R.sup.1 =CH.sub.3,R.sup.2 =H, Cl, Br, I, methyl, hydroxy, methoxy, propoxy, propoxy or ethoxy;R.sup.3 =H or .beta.-D-glykosyl;R.sup.4 =H, Cl, Br, I, methyl, hydroxy, methoxy, propoxy, iso-propoxy or ethoxy;R.sup.5 =H or hydroxy,and the pharmaceutically acceptable salts, ethers and esters thereof, with the exception of the compounds 4-hydroxyacetophenone, 4-hydroxy-3-methoxy-acetophenone, 4-glucopyranosyloxy-acetophenone, 4-glucopyranosyloxy-3-methoxyacetophenone, 4-galactopyranosyloxy-3-methoxy-acetophenone, 4-glucopyranosyloxy-3,5-dimethoxy-acetophenone and galactopyranosyloxy-3,5-dimethoxy-acetophenone and a method for manufacturing them and pharmaceutical preparations containing them. The invention also concerns pharmaceutical preparations containing at least one compound of the formula (II) ##STR2## in which R.sup.1 denotes H, OH, alkoxy or C.sub.1-8 alkyl;R.sup.2 denotes H or C.sub.1-4 alkoxy;R.sup.3 denotes OH or a .beta.

Abstract: The invention relates to new oxidiazole-alkyl-purine-derivatives of the Formula I ##STR1## and pharmaceutically acceptable salts thereof wherein A stands for C.sub.1-4 alkylene andR.sup.1 represents C.sub.1-6 alkyl, hydroxyalkyl, halogenoalkyl, carboxyalkyl, C.sub.5-6 cycloalkyl or aminoalkyl of the Formula --(CH.sub.2).sub.n --NR.sup.2 R.sup.3 in which group n is an integer 1-3; R.sup.2 and R.sup.3 each stand for hydrogen or C.sub.1-4 alkyl or together with the adjacent nitrogen atom they are attached to form a 5- or 6-membered nitrogen containing heterocyclic ring which may optionally comprise a further nitrogen atom or an oxygen atom as heteroatom; orR.sup.1 stands for phenyl, hydroxyphenyl, carboxyphenyl, benzyl or dimethoxybenzylThe compounds of the Formula I can be prepared by methods known per se and can be used in therapy as antitussive agents.

Abstract: 2,6-di-O-methyl-beta-cyclodextrin complexes of compounds of the formula (1a) ##STR1## wherein R.sup.2' stands for C.sub.1 to C.sub.12 alkyl or a group of the formula ##STR2## in which R.sup.11 is C.sub.1 to C.sub.4 alkyl;R.sup.12 is hydrogen or C.sub.1 to C.sub.4 alkyl;n is 0 or 1;p is 1 to 4;r is 1 to 4; andR.sup.3' and R.sup.4' are each C.sub.1 to C.sub.4 alkyl, or pharmaceutically salts thereof are disclosed, having analgesic activity.

Abstract: An animal feed containing 0.00002 to 0.1% by weight of:2-methyl-7-methoxy-4'-nitroisoflavone,7-[hydroxyethoxy]-2-methylisoflavone,7-carbethoxy-2-methylisoflavone,7-ethoxyisoflavone,7-n-benzyloxy-2-methylisoflavone,7-p-nitrobenzyloxyisoflavone,7-p-nitrobenzyloxy-2-methylisoflavone,7-p-chlorobenzyloxyisoflavone,7-cetyloxy-2-methylisoflavone,7-(2-octyloxy)-isoflavone,7-benzyloxy-3',4'-dimethoxyisoflavone, and7-hexadecyloxyisoflavoneAs a weight-gain promoting anabolic ingredient.

Abstract: Compounds of the formula (1), or their salts, ##STR1## are prepared as follows: (A) A COMPOUND OF THE FORMULA (II) ##STR2## is reduced; or (B) A COMPOUND OF THE FORMULA (III) ##STR3## is reacted, e.g. after protecting the phenolic hydroxy group attached to position 3 of the ring, with a compound of the formula (IV), ##STR4## or (C) GROUP R.sup.1 of a compound of the formula (V) ##STR5## is removed in an acidic medium, AND, IF DESIRED, THE COMPOUND OF THE FORMULA (I) is converted into salt, or a salt of a compound of the formula (I) is converted into the free acid or another salt thereof.The compounds of the formula (I) and their salts are valuable artificial sweetening agents.In the above formulae"alkyl" is a C.sub.1-4 alkyl group,R is hydrogen or a protecting group capable of splitting off upon hydrogenolysis, preferably benzyl or benzyloxycarbonyl,M+ is a proton or another cation,X is a group of the general formula O.sup.- M.sup.+,Y is halogen, orX and Y together represent an oxygen atom, andR.sup.

Abstract: A sweetening agent in the form of a 1,3-diphenyl-propanone-1 derivative of the formula ##SPC1##Wherein R is hydrogen, hydroxyl, alkoxy or carboxyl-substituted, sulphonyl-substituted, phosphonyl-substituted, dialkylamino-substituted, trialkyl ammonium-substituted alkoxy; R.sup.1 is hydrogen or a hydrophylic group but both R and R.sup.1 are not both hydrogen; R.sup.2 and R.sup.3 are hydroxyl or alkoxy.

Abstract: A method of anabolic treatment in humans comprises administering a compound of the following formula: ##SPC1##Wherein R is halosubstituted, nitrosubstituted, or unsubstituted benzyl, R.sup.2 is hydrogen, methyl or carboxy, and R.sup.3 and R.sup.4 are hydrogen, methoxy or nitro. Pharmaceutical compositions are also disclosed.